SINGAPORE, July 7, 2026 /PRNewswire/ — GeeLark, a cloud-phone platform for mobile-native social media operations, today commented on Instagram’s expanded originality policies and the growing impact these changes may have on social media teams managing multiple accounts.

Instagram has continued to increase its emphasis on original content across the platform. In late April 2026, the company expanded its policy around unoriginal content beyond Reels to include photos and carousels, limiting recommendation eligibility for accounts that primarily repost content they did not create or significantly modify. The change has been widely viewed as part of Instagram’s broader effort to prioritize original creators and reduce the reach of aggregator-style accounts.

The update comes at a time when social media teams, agencies, creators, and brand operators are already facing greater pressure to produce differentiated content across multiple accounts. For teams that have historically relied on reposting, light curation, or repeated content formats to maintain publishing volume, the shift raises the operational standard for what successful account management now requires.

At the same time, Instagram’s Live feature has also become less accessible to smaller accounts. Since 2025, Instagram has required users to have a public account with at least 1,000 followers to start a live broadcast, creating an additional threshold for early-stage creators and growing accounts that previously used Live as a way to build audience relationships.

Together, these changes point to a broader platform trend: social media growth is becoming less about volume alone and more about originality, account-level differentiation, and consistent mobile-native execution.

For social media professionals, the impact is practical. Content calendars that once depended on reposting or lightly edited assets now require more original production. Agencies managing multiple accounts can no longer rely on near-identical workflows across every profile. Smaller accounts must work harder to build visibility before they can access certain growth formats such as live streaming.

This shift also changes the role of operations. Managing many accounts well now requires workflows that let each account keep its own content strategy, publishing rhythm, and operating environment — not just a shared content calendar.

“Instagram’s originality push reflects a broader change across social platforms,” said Eleanor Xie, CMO at GeeLark. “Platforms are increasingly rewarding accounts that operate authentically and independently. For teams managing more than a handful of accounts, that means investing in better workflows and infrastructure — not just producing more content.”

GeeLark’s cloud-phone platform allows teams to manage Android cloud environments remotely, giving each account its own operating environment while supporting centralized oversight across accounts, campaigns, regions, or brands. Rather than relying only on browser dashboards or post-scheduling tools, teams can use these mobile-native environments to handle the full lifecycle of account operations — publishing, maintenance, profile updates, and campaign testing — directly from the apps these platforms are built around.

As Instagram continues to raise the bar for originality and account quality, GeeLark expects multi-account teams to place greater emphasis on differentiated workflows and mobile-native operations going forward.

About GeeLark

GeeLark is a cloud-phone platform designed for mobile-native operations. By providing Android cloud phone environments, RPA automation tools, and centralized device management capabilities, GeeLark helps marketers, agencies, developers, and businesses streamline social media workflows and manage multi-account operations more efficiently.

Learn more at www.geelark.com.

Powered by Apkudo Device OS™, the compact physical AI system is the only system that automates cosmetic and functional inspection for complex device form factors without hardware reconfiguration

BALTIMORE, July 7, 2026 /PRNewswire/ — Apkudo, the Device Passport™ Platform company, today announced the commercial launch of the Robotic Standalone Automation (RSA) appliance. Engineered by Alpha Automatics and available exclusively through Apkudo, RSA is the first automated processing solution capable of handling the full spectrum of modern device form factors, including flip devices, foldables, and tablets, without requiring hardware reconfiguration between operational runs. The system runs on Device OS, Apkudo’s foundational platform layer that enables an open ecosystem of robotics manufacturers to build, deploy, and operate advanced device processing solutions.

While consumer adoption of flexible screens continues to accelerate, driven by highly anticipated product cycles and 24% year-over-year growth in foldable shipments (Counterpoint Research), these form factors have simultaneously become among the fastest-growing and most operationally challenging segments in mobile returns. Manual handling of foldables and tablets introduces severe grading subjectivity, slows down warehouse processing throughput, and limits the depth of verified condition data available for downstream resale programs. This processing bottleneck affects participants throughout the reverse logistics ecosystem who lack access to standardized, high-volume automation designed for modern device shapes.

The RSA appliance solves these challenges by processing smartphones, tablets, and foldable devices on a single system for precise cosmetic and functional testing with no hardware or software reconfiguration between runs. It completely eliminates manual handling and operator subjectivity in device testing and analytics. The system uses advanced robotics, integrated torque sensors, and acoustic capture to deliver precise foldable diagnostics. For larger display surfaces like tablets, the system uses stitched high-resolution imaging to preserve per-pixel detail. Apkudo’s cosmetic Device AI™ models enable robust defect detection and are compliant with the CTIA 5.1 grading standard. All generated data automatically streams to the Apkudo Platform to populate a unique Device Passport.

“Being powered by Apkudo allowed us to apply our hardware engineering expertise to an intricate industry challenge,” said Charles Xie, CEO of Alpha Automatics. “The RSA appliance provides the structural precision required to handle modern, flexible form factors safely and efficiently, creating a zero-touch compact system that integrates seamlessly into existing physical workflows.”

“RSA brings the same physical AI precision the Apkudo platform delivers for standard devices to the form factors that have historically challenged the reverse logistics industry,” said Josh Matthews, CEO and Co-Founder of Apkudo. “By using Device OS as our platform software layer, we can empower hardware innovators like Alpha Automatics to help the industry solve the foldable and tablet segment at scale, giving operators absolute data veracity without the high operational costs of manual workflows.”

Designed for straightforward deployment, the system fits through standard industrial doorways and processes up to 30 devices per hour. This agile footprint makes the unit excellent for smaller regional sellers processing as few as 5,000 units per month who want to introduce automation without major warehouse layout overhauls. Simultaneously, mid- and large-sized return centers can link multiple units, conveyor to conveyor, to scale capacity incrementally as volumes grow. High-volume centers can deploy the system as a specialized standalone workcell, extending automated diagnostics to complex device types that legacy point solutions cannot accommodate. OEM-specific RSA cells have been operational for more than a year, and initial commercial deployments are currently underway with ecosystem leaders including Likewize, MTR, and TMT First.

You can learn more about RSA at Mobile Disrupt 2026, July 7–8, in Miami. Visit Apkudo at booth #1001–1002. Learn more at apkudo.com.

About Apkudo
Apkudo is the Device Passport Platform for the connected device ecosystem. We capture and unify data from every program, transaction, and touchpoint across a device’s lifecycle, creating a single, trusted Device Passport™ for every asset. For companies that manage, sell, or buy devices, this means a verified record they can act on: to restore buyer confidence, maximize value, and reduce risk at every decision point. Our unique advantage is data fidelity and veracity, built on precision-automated robotics that have processed millions of devices, generating objective, machine-verified data that no competitor can match. To learn more, visit apkudo.com. 

Media Contact:
Kristen Barry
SVP Marketing and Communications
kristen.barry@apkudo.com 

Minimises Cardiopulmonary Concerns and Maintains Quality of Life

HONG KONG, July 7, 2026 /PRNewswire/ — The HKSH Cancer Centre under HKSH Medical Group (HKSH) introduced proton therapy in 2023, covering a wide range of cancer types including breast, prostate as well as head and neck cancers, and has since accumulated about 940 cases of clinical data. Around 45% of its proton therapy treatments involve breast cancer patients receiving postoperative radiotherapy to reduce the risk of recurrence. Leveraging its clinical experience and innovative technologies in breast cancer proton therapy, HKSH has presented two clinical studies focusing on Chinese breast cancer patients at the Asia-Oceania Particle Therapy Co-operative Group 2025 (PTCOG-AO) and Particle Therapy Co-operative Group Annual Conference 2026 (PTCOG). Both studies are the first of their kind in Asia and further advance precision medicine aimed at helping patients “live with cancer while preserving quality of life.”

Mr. Wyman LI, Chief Operating Officer of HKSH Medical Group and Director of Hong Kong Sanatorium & Hospital, remarked, “Clinical research is the core driving force behind medical innovation. HKSH Proton Therapy Centre has demonstrated strong research depth on the international academic stage, injecting powerful momentum into precision cancer treatment for Hong Kong and the Greater Bay Area. At the same time, HKSH actively introduces cutting‑edge technologies, including being Asia’s first to adopt photon‑counting CT for simulation and treatment planning. Shouldering the responsibility of nurturing national proton therapy professionals, HKSH collaborated with the National Cancer Centre in 2025 to launch a joint training course and a 10-month training programme, leveraging technological innovation and clinical excellence to provide patients and their families with more precise and effective disease management services.”

The first study presented in the PTCOG-AO 2025 compared proton radiotherapy with conventional photon radiotherapy in preventing breast cancer recurrence after surgery. Results showed that both treatment modalities achieved comparable disease control, with a 100% survival rate in each group.* However, modern cancer care places increasing emphasis on reducing side effects and long-term complications. The study demonstrated that proton therapy offers a distinct advantage in dose precision, reducing radiation exposure to the heart during breast cancer treatment to nearly zero, approximately up to 40 times lower than photon therapy, while only a very small number of patients experienced Grade 2 or higher toxicities.

The second study explored a hypofractionated regimen consisting of just five sessions of proton therapy for breast cancer. This approach substantially reduces the need for frequent hospital visits, lowers overall treatment time and costs, and alleviates psychological burden on patients. Combining a shorter treatment duration with high precision and strong clinical effectiveness, the regimen represents a key strategic direction for delivering more cost-effective proton therapy to breast cancer patients at HKSH.

Dr. Amy CHANG, Co-Director of HKSH Proton Therapy Centre and Specialist in Clinical Oncology, commented, “With the growing uptake of breast cancer screening, more patients are being diagnosed at an earlier stage. As survival rates improve, quality of life has become a key consideration. Treatment options with fewer side effects, such as proton therapy, are therefore increasingly important, enabling patients to maintain a good quality of life while effectively controlling their disease.”

Photon Therapy Minimises Unnecessary Radiation Exposure to the Heart and Lungs
The first study was a retrospective matched comparative study involving 202 Chinese breast cancer patients arranged in a matched cohort for comparison. The median ages of the two groups were 51 and 52, with stages 0 to III, predominantly left-sided breast cancer patients, who underwent 5 to 25 fractions of proton or photon radiotherapy. All patients had undergone partial or total mastectomy. However, due to the risk of breast cancer recurrence, adjuvant therapy is generally required post-surgery to eliminate residual lesions, and radiotherapy is one of the primary modalities.

Apart from conventional photon therapy, proton therapy is a more advanced and precise treatment option. To explore the efficacy of both in preventing recurrence and their safety, the study used 1:1 Propensity Score Matching (PSM) based on factors including patient’s age, tumour location, staging, treatment fraction, histology type and medical history to compare two groups: one receiving conventional photon therapy between 2020 and 2024, and the other receiving proton therapy between 2023 and 2025, with 101 patients in each group.

Dr. Amy CHANG explained, “Study reveals that the survival rate of both groups during the follow-up period is 100%, including stage III breast cancer patients with larger tumours and more lymph node metastases. The results are highly encouraging.” To more comprehensively help patients overcome treatment challenges, treatment safety must be examined. In photon therapy, radiation not only exposes the tumour but also penetrates through to the heart and lungs behind the tumour, leading to long-term impact such as heart disease and pneumonitis. In contrast, proton therapy exhibits ultra precision, targeting the tumour with radiation energy released in a concentrated burst upon reaching the tumour, while ensuring that radiation dose drastically drops and dissipates afterwards, thereby minimising damage to surrounding healthy organs.

This study showed that all dose parameters in the proton therapy group were superior to those in the photon group, especially in relation to the heart and lungs. The average heart radiation dose received by patients in the proton group was close to 0 Gy (Gray, abbreviated Gy, the unit of absorbed radiation dose), at only 0.28Gy (25-fraction proton) and 0.12 Gy (15-fraction proton), compared to 5.34 Gy (25-fraction photon) and 4.71 Gy (15-fraction photon)—a difference of approximately 20 to 40 times. Dr. CHANG remarked, “Earlier research data has shown that for every 1Gy increase in heart radiation dose, the risk of heart disease rises by 7.4%. Therefore, proton therapy can minimise unnecessary radiation exposure to the heart, significantly reducing patients’ risk of cardiovascular disease.”

Hypofractionated Proton Therapy Results in Low Toxicity, Minimising Skin Damage
Overcoming cancer and returning to a normal life is the common goal of all cancer patients. Given the current trend of breast cancer diagnosed at younger ages, quality of life is a critical factor in choosing a treatment plan. Dr. CHANG highlighted that in this matched comparative study, only a small number of patients in the proton therapy group experienced grade 2 or higher severe toxicity reactions (toxicity graded from 0 to 3, with 3 being the most severe). Regarding skin-related reactions including radiation dermatitis which is a major concern for women, the proportion of patients in the proton group experiencing grade 2-3 toxicity was 3% lower than that in the photon group. In terms of late toxicity, the proton group also had 10% fewer cases of grade 1 breast edema compared with the photon group. This shows that hypofractionated proton therapy can better preserve the breast appearance and skin integrity of patients, alleviating their psychological burden.

5-Fraction Proton Therapy Helps Patients Maintain Quality of Life
As of 30 June 2026, HKSH Proton Therapy Centre has performed about 940 proton therapy cases, with breast cancer accounting for about 45%, accumulating clinical experience with more than 400 patient cases. Compared to other proton therapy centres in the region, HKSH has extensive clinical experience in proton therapy for breast cancer. To explore more cost-effective “hypofractionation” treatment methods in line with international medical trends, the team launched a clinical study** on 5-fraction proton therapy for breast cancer in 2024 and presented preliminary data at the PTCOG 2026.

The preliminary data followed 27 patients with stage 0-II breast cancer, 70% of whom had left-sided breast cancer. All patients completed 5 fractions of whole-breast proton therapy totaling 25 Gy. Dr. CHANG who led this study said, “The study recorded zero cases of grade 2 or higher acute severe toxicity. The main side effects were mild dermatitis, fatigue, and breast pain.” The study also assessed patients using Harvard Cosmesis Scale, proving that proton therapy had minimal impact on appearance with no obvious changes. Multiple quality of life indicators also showed a trend of continuous improvement compared to baseline pre-treatment levels, enhancing post-recovery quality of life.”

Supported by solid clinical data and innovative research, the goal of cancer treatment has expanded from simply eradicating cancer cells to a broader strategy that takes long-term quality of life into account. Given its favourable outcomes and high safety profile, HKSH Cancer Centre has now incorporated 5-fraction proton therapy for breast cancer as one of its treatment options, allowing for flexible and personalised treatment plans tailored to individual patients’ conditions, taking precision cancer care to the next level.

* Clinical Outcomes and Toxicity of Proton Therapy for Breast Cancer: A Single Institution Study. PTCOG-AO-2025.
** Biopsychosocial Study on Ultrahypofractionated Proton Therapy for Breast Cancer Patients: Early Clinical Outcome. PTCOG 2026.

About HKSH Medical Group
Officially launched in September 2017, HKSH Medical Group promotes public health and advanced medicine through a multi-faceted, coordinated approach across clinical services, medical education, scientific research and public health education. Members of the Group, including Hong Kong Sanatorium & Hospital, HKSH Healthcare, HKSH Eastern Medical Centre, HKSH Cancer Centre and HKSH Institute for Innovation & Professional Development, are dedicated to offering top-quality holistic care to patients.

Established in 1922, Hong Kong Sanatorium & Hospital is one of the key members of HKSH Medical Group and a leading private hospital in Hong Kong. Living up to its motto of ‘Quality in Service, Excellence in Care’, the Hospital is committed to serving the public as well as promoting medical education and research.

For more information about HKSH Medical Group, please visit http://www.hksh.com.

KUALA LUMPUR, Malaysia, July 7, 2026 /PRNewswire/ — Hoymiles announced a strategic partnership with TAMCO, a well-established power infrastructure solutions provider in Malaysia, to support the development of the country’s future energy infrastructure. This collaboration combines Hoymiles’ globally deployed energy storage technologies with TAMCO’s six decades of local industrial expertise, marking another significant step in Hoymiles’ utility-scale energy storage sector as well as its expansion across Southeast Asian markets. Top executives from both sides and representatives from Malaysian Investment Development Authority (MIDA) attended the signing ceremony.

For the first phase of the collaboration, TAMCO will locally assemble Hoymiles’ AI-empowered 5MWh and 6MWh liquid-cooled utility-scale BESS solutions at its BR2 facility in Shah Alam. By combining Hoymiles’ globally proven energy storage technologies with TAMCO’s extensive engineering expertise and local manufacturing capabilities, the partnership will make advanced energy storage solutions more accessible to the local market and provide comprehensive support for utility-scale projects across Malaysia.

In addition to local assembly, the partnership also includes system integration, testing, commissioning, servicing and long-term maintenance, ensuring a comprehensive local delivery and lifecycle support framework for utility-scale energy storage projects.

“Our partnership with Hoymiles represents an important step in expanding the solutions we deliver while strengthening the engineering expertise and technical capabilities needed for the country’s future energy infrastructure,” said Wong Jun Pin, Chief Executive Officer of TAMCO Switchgear (Malaysia) Sdn. Bhd.

Stressing the importance of trusted local partnerships in the success of advanced energy solutions, Dr. Zhao Yi, Chief Technology Officer and Vice President of Hoymiles, said, “Malaysia has built a strong foundation for the future of energy, and TAMCO’s engineering expertise and deep understanding of the local operating environment make them an ideal partner to translate our global experience into solutions that deliver value locally.”

Sherulanuar Abd. Karim, Director of Malaysian Investment Development Authority (MIDA) noted that the collaboration demonstrates how international partnerships can strengthen Malaysia’s industrial capabilities while supporting the country’s clean energy transition.

Malaysia is one of Southeast Asia’s fastest-growing renewable energy markets and a key market in Hoymiles’ regional energy storage strategy. In recent years, Hoymiles has continued to strengthen its local presence through a series of landmark solar-plus-storage projects.

Building on this partnership, Hoymiles and TAMCO will work together on technology exchange, talent development and localization initiatives, supporting Malaysia’s energy infrastructure development and long-term energy transition.